Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Inclusion Criteria

• •Patients with relapsed or refractory CD5+ NK and T-cell originated malignancies (per WHO classification 2017).
• •Patients with relapsed or refractory disease previously treated with two or more lines of standard chemotherapies and there is no longer any treatment option considered as assessed by the Investigator.
• •According to the Lugano classification, patients having lesion/nodules ≥ 1 with diameter longer than 1.5 cm for nodal lesions and longer than 1.0 cm for extranodal lesions, and the boundaries are clearly shown.
• •Patient has a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.
• •Patients who satisfy the criteria defined in the protocol.
• •Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.